UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2010
Commission
File Number: 001-34541
CHINA
CORD BLOOD CORPORATION
(Translation
of registrant’s name into English)
48th
Floor, Bank of China Tower
1 Garden
Road
Central
Hong Kong
S.A.R.
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o
No x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-_______________.
Other
Events
On November 4, 2010, China Cord Blood
Corporation (the “Company”) issued a press release announcing it intents to
complete a follow-on offering of ordinary shares, including ordinary shares that
may be offered and sold by certain selling shareholders upon the exercise of an
option granted to the underwriters to cover over-allotments. A copy
of the press release is attached as Exhibit 99.1.
Exhibits
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated November 4,
2010
|
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
CHINA CORD BLOOD
CORPORATION
|
|||
|
|
By:
|
/s/ Albert Chen | |
| Name: | Albert Chen | ||
| Title: | Chief Financial Officer | ||
Dated: November 4,
2010
3
China
Cord Blood Corporation Announces
Proposed
Public Offering of Ordinary Shares
HONG
KONG, China, November 4, 2010 - China Cord Blood Corporation (NYSE: CO) (“CCBC”
or “the Company”), the first and largest cord blood bank operator in China,
today announced that it intends to offer and sell its ordinary shares in an
underwritten offering. Jefferies & Company, Inc. is the sole bookrunner for
the offering. The offering is subject to market conditions, and there
can be no assurance as to whether or when the offering may be completed, or as
to the actual size or terms of the offering.
The
Company is conducting the offering pursuant to an effective shelf registration
statement previously filed with the Securities and Exchange Commission (the
“SEC”). A preliminary prospectus supplement related to the offering
is being filed with the SEC and is available on the SEC’s website at http://www.sec.gov.
Copies of the preliminary prospectus supplement relating to these securities may
be obtained from Equity Syndicate Prospectus Department, Jefferies &
Company, Inc., 520 Madison Avenue, 12th Floor,
New York, NY, 10022, at 877-547-6340, and at [email protected].
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any such
state or jurisdiction. The offering may only be made by means of a
prospectus supplement and related base prospectus.
About China Cord Blood
Corporation
China
Cord Blood Corporation is the first and largest cord blood banking operator in
China in terms of geographic coverage and is the only cord blood bank operator
in China with multiple licenses. Under the current PRC government
regulations, only one licensed cord blood bank operator is permitted to operate
in each licensed region and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood collection,
laboratory testing, hematopoietic stem cell processing, and stem cell storage
services.
Forward-Looking
Statements
This
press release contains forward-looking statements as defined by the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future events,
performance and results of operations, and underlying assumptions and other
statements that are other than statements of historical facts. These statements
are subject to uncertainties and risks including, but not limited to, product
and service demand and acceptance, changes in technology, economic conditions,
the impact of competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the Company, are expressly qualified by the
cautionary statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims any
obligation to update any forward-looking statements to reflect events or
circumstances after the date hereof. Completion of the proposed offering is
subject to market conditions and other factors.
For more
information, please contact:
China
Cord Blood Corporation
Ms.
Joeling Law
Tel:
(+852) 3605-8180
Email:
[email protected]
ICR,
LLC
In New
York: Ashley M. Ammon or Christine Duan: 1-646-277-1227
In
Beijing: Wen Lei Zheng: +86-10-6599-7968